MGTX
MeiraGTxDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
Bull case assumes positive clinical readouts and at least one partnering/licensing deal within three months that materially de-risks programs and accelerates milestones, prompting re-rating versus peers.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -3.1.
What can break
Clinical trial failure or safety signal
Momentum
74
Value
41
Sentiment
19
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.33 · Bull $9.38 · Bear $3.52
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $26.75
Why
Momentum74 · Δ7d -3.1
Value41 · Δ7d +0.0
Sentiment19 · Δ7d +3.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
74
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.1
Δ21d
-10.5
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
19
33% active weight
Current posture
7d trendImproving
Δ7d
+3.6
Δ21d
+10.0
Why this grade
Composite grade D. Momentum 73.8 / Value 41.1 / Sentiment 19.5
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$855.71M
Beta
1.38
Shares Out
80.49M
P/E (TTM) · Derived
-5.0
P/S (TTM)
22.17
P/FCF (TTM) · Derived
-7.02
Rev YoY
-96.2%
EPS YoY
-13.7%
Gross Margin
+41.0%
Op Margin
-597.9%
Net Debt
-$30.44M
Current Ratio
0.22
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology